Description
Bravylol contains nebivolol, a selective β1-blocker, which reduces heart rate, blood pressure and peripheral systemic vascular resistance.
Indications
Bravylol is indicated for the treatment of:
– essential hypertension;
– stable mild and moderate chronic heart failure in addition to standard therapies in elderly patients (>70 years).
Subject to medical prescription.
Concentration and pharmaceutical form: 5 mg tablets
Description
Pisizif SR contains indapamide – a non-thiazide sulphonamide diuretic. Most diuretics increase the amount of urine produced by the kidneys. Indapamide increases the urinary secretion of sodium and chloride ions and, to a lesser extent, the excretion of potassium and magnesium, thus increasing urine output and having an antihypertensive effect.
Indications
Pisizif SR is indicated for the treatment of essential hypertension.
Subject to medical prescription.
Concentration and pharmaceutical form: 1,5 mg prolonged release tablets
Description
Peximyr contains the active substance pramipexole and belongs to a group of medicines known as dopamine agonists, which stimulate dopamine receptors in the brain. Stimulation of the dopamine receptors triggers nerve impulses in the brain that help to control body movements.
Indications
Peximyr is used to:
– treat the symptoms of primary Parkinson’s disease in adults. It can be used alone or in combination with levodopa (another medicine for Parkinson’s disease);
– treat the symptoms of moderate to severe primary Restless Legs Syndrome in adults.
Subject to medical prescription.
Concentration and pharmaceutical form: 0,18 mg; 0,7 mg tablets
Description
PlaquEx contains clopidogrel and belongs to a group of medicines called antiplatelet medicinal products. By preventing this clumping, antiplatelet medicinal products reduce the chances of blood clots forming.
Indications
Secondary prevention of atherothrombotic events
Clopidogrel is indicated in:
– adult patients suffering from myocardial infarction (from a few days to 35 days), ischaemic stroke (from the 7th day to the 6th month) or established peripheral arterial disease;
– adult patients suffering from acute coronary syndrome:
– non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (ASA).
– ST segment elevation acute myocardial infarction, in combination with ASA in medically treated patients eligible for thrombolytic therapy.
Prevention of atherothrombotic and thromboembolic events in atrial fibrillation
In adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with Vitamin K antagonists (VKA) and who have a low bleeding risk, clopidogrel is indicated in combination with ASA for the prevention of atherothrombotic and thromboembolic events, including stroke.
Subject to medical prescription.
Concentration and pharmaceutical form: 75 mg film-coated tablets
